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Abstract: The most appropriate strategy and timing for surgery in infective endocarditis (IE) remains
an argument of debate. Despite some authors promote the adoption of an early surgical approach (within
48 hours) to limit mortality and complications, no robust randomized trials are available on this argument
and the evidence on this subject remain at the “expert opinion” level. Additionally, the different messages
promulgated by the American and European guidelines contributed to fuel confusion regarding the
relative priority of the surgical over medical therapy in IE. The European Society of Cardiology (ESC)
guidelines individuates three level of urgency: emergency surgery, to be performed within 24 hours; urgent
surgery, recommended within a few days; elective surgery to be performed after 1–2 weeks of antibiotic
therapy. Urgent surgery is recommended for most cases of IE. In the American Heart Association (AHA)’s
guidelines define early surgery as “during the initial hospitalization and before completion of a full course
of antibiotics.” Some of the available evidences showed that are no proven benefits in delaying surgery if a
definite diagnosis of IE has been established. However, this argument is controversial across the literature
and several factors including the center specific experience can play a role in decision-making. In this review
the latest evidences on IE clinical and surgical characteristics along with the current studies on the adoption
of an early surgical approach are analyzed to clarify whether enough evidence is available to inform an update
of the guidelines.
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Introduction
Despite the progress achieved in recent years for the treatment
of infectious endocarditis in both the medical and surgical
fields, this clinical-pathological entity remains a serious disease
carrying a significant risk of death and morbidity (1-4). The
use of surgery has gained momentum in the treatment of
infectious endocarditis and it is expanding. However, current
guidelines are cautious in supporting broad application of
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surgery in complicated left-sided infectious endocarditis
(2,5,6). Although early surgery is highly recommended in
patients with infective endocarditis (IE) who present with signs
of congestive heart failure (3-6), the indications for surgery
to prevent systemic embolism remain undefined (7-9). The
main concern is for patients with large vegetation and a high
risk of embolism (4,10). In these patients’ early surgery with
complete excision of infected tissue and valve repair have
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been achieved in high-volume centers with low mortality
suggesting the benefit of early surgical management (1,4-6,11).
However, concerns remain regarding the technical challenge
of performing surgery in the presence of active infection and
inflammatory response (1,12).
The 2014 American College of Cardiology-American
Heart Association (ACC-AHA) guidelines (13) recommend
the use of early surgery as class IIa indication only in
patients who have recurrent emboli and persistent
vegetation. Instead, the guidelines of the European Society
of Cardiology (ESC) (6) recommend the use of early
surgery as class IIb indication in patients who have isolated
and very large vegetations (>15 mm in diameter). The nonunivocal recommendation from the two Society guidelines
and the lack of randomized studies related to the presence
of ethical, logistical, and financial constraints, impede to
clarify the best indications for surgery and its timing (6).
The best timing for surgery is even more important in
patients with prosthetic valve endocarditis (PVE), which
present in 3% to 6% of the patients within 5 years of surgery
and is associated with significant morbidity and mortality
(14-17). Surgical debridement and valve replacement are
recommended by consensus guidelines (6,14) in patients
with IE who experience complications such as valve
dysfunction, dehiscence, heart failure, cardiac abscess,
or persistent bacteremia. However, these guidelines rely
largely on expert opinion and limited observational data (18).
There are several studies that have compared survival
between patients undergoing surgery and medical therapy
for PVE but they have reported conflicting results
(15,18-25). Furthermore, their retrospective nature, low
sample size and risk for treatment allocation bias profoundly
limit the power of these studies.
The only randomized evidence comparing the use of
early surgery to medical treatment enrolled only a small
number of patients with native valve endocarditis due to
the streptococcal pathogen (26). No randomized studies on
PVE are currently available.
The objective of this review is to evaluate whether an
answer can be given on the question regarding the best
strategy to be adopted in the early treatment of IE.
We present the following article in accordance with the
Narrative Review reporting checklist (available at http://
dx.doi.org/10.21037/atm-20-3880).

“endocarditis”, “left side endocarditis “, “right side
endocarditis”, “aortic valve endocarditis”, “mitral valve
endocarditis”, “tricuspid valve endocarditis”, “heart valve
prosthesis”, “allograft”, “autograft”, “cardiac valve surgery”,
“early surgery”, “delayed surgery”, was coordinated.
Qualified abstracts were independently reviewed by two
investigators and the related articles were evaluated.
References for all selected studies were cross checked.
Data from randomized controlled trials (RCT), unmatched
observational series, observational series corresponding to
propensity, meta-analysis, registries, and expert opinion
were included.

Methods

Hemodynamic decompensation and heart failure

A search of the PubMed database using the terms

The most common indication to perform early operation
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Clinical evidence
Patient presentation
Patients with sepsis of unknown origin or fever in the
presence of risk factors should always trigger the suspicion
of IE. They should have a careful assessment of symptoms
and should undergo a clinical and microbiological
investigation followed by transthoracic echocardiography
to assess the mechanism and severity of heart valve
infection, as well as left ventricular size and function. The
manifestations of sepsis can fluctuate from general malaise
to shock because they are influenced both by the virulence
of the pathogen and by the host’s immune response (27,28).
Usually Gram-positive Cocci of the staphylococcus,
streptococcus and enterococcus species are responsible for
80–90% of infectious endocarditis. S aureus is the most
frequently isolated pathogen in infectious endocarditis in
high-income countries with a reported percentage of 30%
of cases (29,30). In particular, a microbiological diagnosis
of S aureus bacteraemia is associated with infectious
endocarditis in 25–30% of cases and all patients must be
received echocardiography (31,32).
Patients with IE who present in a critical phase should be
judiciously evaluated for risk of embolism and hemodynamic
deterioration towards heart failure. Risk factors as
underlying hemodialysis or addiction to the intravenous
drug should be considered (33). The infection can be
localized on the native and prosthetic valves, and patients
might be asymptomatic without clinical cardiovascular
deterioration for few days after infection (Figure 1).
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Figure 1 Pathway for Management of IE. ACC/AHA, American College of Cardiology/American Heart association; CAD, coronary artery
disease; EROA, effective regurgitant orifice area; ESC, European Society of Cardiologists; FA, atrial fibrillation; IE, infective endocarditis;
LV, left ventricle; LA, left atrium; PASP, pulmonary artery systolic pressure; TTE , transthoracic echocardiography; RF, regurgitant fraction;
Rvol, regurgitant volume.

in patients with IE is the development of heart failure.
Increasing severity of valve regurgitation, even among
asymptomatic patients, imposes a volume load on the left
ventricle, which, if sustained over time, results in ventricular
dilatation, hypertrophy, neurohormonal activation, and
heart failure. In addition, in presence of a mitral valve
endocarditis elevation in the mean left atrial pressure leads
to left atrial enlargement, atrial fibrillation, pulmonary
congestion, and pulmonary hypertension. Valve obstruction
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is another factor determining hemodynamic instability
and heart failure. Evidence from numerous cohort studies
revealed that the results were nefarious in patients who had
not received emergency surgery because of the progression
to pulmonary edema or cardiogenic shock (4,34-36).
The presence of a large vegetation that compromises the
functionality of the entire valve—rarely only a single leaflet
is involved—can have a faster deterioration with progression
of hemodynamic instability. These patients have valves
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Figure 2 Clinical Algorithm for the Management of IE. CT, computed tomography; GDMT, guide direct medical therapy; MRI, magnetic;
PET/CT, positron emission; TEE, transoesophageal echocardiography TTE, transthoracic echocardiography; SPECT, single-photon
emission computed tomography.

seriously affected by infection with a cauliflower-like lesion
(4,37). In patients with limited degree of valve regurgitation
valve regurgitation surgery can be deferred surgery after a
period of stabilization with antibiotic therapy, but there are
no randomized controlled clinical trials that satisfactorily
guide clinical practice in this area (37,38) (Figure 2).
Etiology of Infection
Coagulase negative staphylococci (e.g., staphylococcus
epidermidis, Staphylococcus lugdunensis and
Staphylococcus capitis) are omnipresent cutaneous
commensals that are implicated in complicated infectious
endocarditis. They can colonize native heart valves and
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are the most common pathogens isolated in early PVE
(19,21,39). It is not uncommon for coagulase negative
staphylococci to cause hospital-acquired native valve
endocarditis (40). In general, three blood culture series
detect the presence of these pathogens in 96–98% of
patients with bacteremia who have not yet started treatment
with antibiotics (41,42). Blood culture does not need to
be done at the febrile peak because the presence of the
pathogen in the blood is not related to the extent of the
fever. It is possible that patients in a compromised clinical
condition have no pathogen growth from blood cultures
delaying diagnosis (4). This situation is reported in up to
10% of cases and it is linked: (I) to the early administration
of antibiotics before blood cultures; (II) to the sustained
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infection by slow-growing pathogens or fungi and (III) to
particular conditions in which an alternative diagnosis of
non-bacterial thrombotic endocarditis is can be made as in
patients with advanced cancer (43).
Infection related due to Viridans streptococci vehicle
by oro-pharyngeal transmission remains more common in
low-income countries (44). Serial blood cultures can lead to
the discovery of Streptococcus mutans, Streptococcus salivarius,
Streptococcus anginosus, Streptococcus mitis and Streptococcus
sanguinis. Of particular interest is the role played by group
D streptococci (e.g., Gallolyticus Streptococcus, Streptococcus
bovis) that are involved in the IE in patients with a coexisting
colon tumor, which provides the portal circulation as a
route of entry. The pathogens belonging to the group of
Enterococci represent 10% of the overall cases (29,30).
Other forms of endocarditis are related to zoonotic
infection as Coxiella burnetii, Brucella (cattle), Bartonella
henselae (from cats) and Chlamydia psittaci (as parrots,
pigeons).
Infections caused by Gram-negative bacteria (e.g.,
Acinetobacter spp, Pseudomonas aeruginosa) and Legionella spp,
Mycoplasma spp and Tropheryma whippelii can be of particular
concern (45). Furthermore, fungal endocarditis, usually
caused by Candida or Aspergillus, are very aggressive and
often fatal because it occurs in the immunosuppressed
patient or after cardiac surgery, mainly in the prosthetic
valve recipients (46).
A causative pathogen for IE can be identified in about
two thirds of patients by additional microbiological
tests (47). If the patient has negative cultures at 5 days,
serological tests for Coxiella and bartonella are indicated
and if these is also negative, the next step should involve
testing for brucella, Mycoplasma, Legionella, and
chlamydia (48). In the presence of an unrecognized
infection, prolonged blood culture after 7 days does
not provide further useful yields, even for the HACEK
bacteria, which are typically slow-growing (48,49). After
surgery the possibility of having samples the valve, can
help in the microbiological diagnosis through the use
of complementary molecular techniques as polymerase
chain reaction for pathogen DNA (PCR) (50-52). These
techniques are particularly useful in patients that received
antibiotics, as bacterial DNA often persists even for noncultivable pathogens such as T whipplei (51,53).
However, PCR carries the risk of a false positive result
due to contamination of the sample. Clearly in this case
PCR should not be used to guide the duration of therapy.
New techniques combining PCR and mass spectrometry
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promise direct characterization of bacteria in peripheral
blood or valvular tissue (51).
During the IE a very important factor is the host immune
response where the macrophages play a key role (54).
In the most fragile patients and in the presence of very
aggressive pathogens infection can be spread beyond the
valve annulus. The use of echocardiography plays a key role
in the diagnosis and identification of anatomopathological
complications resulting from the progression and
expansion of the infection. Extension of the lesion inducing
the formation of abscess, pseudoaneurysm, fistula, or
atrioventricular block define a complex IE. Although
transthoracic echocardiography (TTE) is sensitive (75%)
and specific (more than 90%) for detection of a vegetation,
transoesophageal echocardiography (TOE) is required for
detection of complicated extensive lesion because it offers a
sensitivity of more than 90% (55). The TOE colour doppler
analysis can reveal a pseudoaneurysm, i.e. a perivalvular
cavity that communicates with the cardiovascular lumen.
Conversely, an abscess is a thickened, pus-filled perivalvular
cavity that has no such communication. A progressive
perivalvular infection can evolve into the formation of
fistula whose pathoanatomical feature is usually an aortocavitary aspect. The onset of this complication is burdened
by a mortality rate greater than 40% even with surgery (56).
For patients with persistent or relapsing infection or
infection caused by aggressive or antibiotic-resistant
microorganisms (e.g., lugdunensis, pseudomonas, fungi)
there is an indication for emergency surgery (57) (Figure 2).
Risk of embolism
The risk of embolism with devastating complication
occurs for a percentage of 25–50% of patients with IE (10).
In the presence of left side endocarditis, the onset of a
stroke is more common than infarction at level of the
kidneys, spleen, limbs, mesenteric and coronary arteries.
Furthermore, the localization of septic emboli in the
context of the vascular structure can provoke a secondary
infection related to the colonization of the “metastatic”
vegetations. The inflammatory process that arises in
the vascular wall is the cause of formation of a mycotic
aneurysm. This lesion develops more frequently in the
cerebral vessels and are visible on brain imaging in 3–5%
of patients with IE, although in most cases they can remain
clinically silent (10,58-60). The IE that are localized in
right-sided of the heart are potentially at risk to determine
lung embolism, or systemic embolism in patients
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presenting a patent foramen ovale. In a large percentage
of patients emboli give a clinical manifestation in the
first 2 weeks after the diagnosis and the risk decreases
rapidly after the initiation of therapy with antibiotics
(61,62). Vilacosta et al. (61) evaluated the risk of systemic
embolization in 217 patients with left-sided IE who had
initiated an adequate antibiotic treatment. In patients
undergoing antibiotic therapy reduced rate embolic
events was observed [12.9% vs. 87.1%; relative risk of new
embolization (RR) 1.73; 95% CI, 1.2 to 2.93; P=0.05].
The majority of emboli (52%) affected the central nervous
system, and 65% of the embolic events occurred during
the first two weeks after initiation of antibiotic treatment.
The authors showed that there was an increased risk of
embolization parallel to vegetation size (RR 3.77, 95% CI
from 0.97 to 12.57; P=0.07). In addition, both the presence
of large (>10 mm) vegetation caused by staphylococcal
Aureus pathogens (P=0.04) and the location on the mitral
valve (P=0.03) had a higher incidence of embolism (61).
In another report, 1,437 patients with IE were studied
to determine the relationship between the initiation of
antimicrobial therapy and the temporal incidence of
stroke. During the study, the approximate incidence of
stroke in patients receiving appropriate antimicrobial
therapy was 4.82/1,000 patient days in the first week of
therapy with a reduction to 1.71/1,000 patient days in the
second week. Note that after one week of antimicrobial
therapy, only 3.1% of the cohort had a stroke and reduced
stroke rates was evident regardless of the type of valve or
pathogen involved (62).
In patients who have experienced a stroke, surgery
should not be postponed in cases with no coma and cerebral
hemorrhage (class IIa, level B). In patients with neurological
diagnosis of minor brain events, such as transient ischemic
attack or silent cerebral embolism, the criterion is to
recommend surgery without delay (class 1, level B) (5).
Conversely, in patients who have experienced devastating
neurological events such as intracranial hemorrhage and
brain localization of septic emboli with hemorrhagic
evolution intervention should be delayed for at least 1
month. In this category of patients it is recommended to
perform CT scans or MRI perfusion scan to evaluate the
progression of the lesion according to the guidelines (class
IIa, level B) (5). Okita et al. specific investigations revealed
that early surgery (<7 days) demonstrated safety and efficacy
in patients included in class I and IIa level B without
preoperative haemorrhagic stroke (63). CT scans repeated
immediately before surgery can rule out hemorrhagic
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evolution of cerebral infarction or the development of
mycotic aneurysm (64) (Figure 2).
Clinical considerations
Over the past 20 years 7 RCT were published on antibiotic
treatment (65-70), but only one RCT (26) investigated the
comparison between medical therapy and early surgery
within 48 hours. Thus, conclusive evidence to indicate
which of these interventions is superior is missing.
In patients with IE the use of early surgery performed
within 48 after diagnosis revealed a decrease in the rate of
death from any causes as well as a reduction of the risk of
systemic embolism (4,5,26,71,72). The concern related to
the use of early surgery may be related to an increase in
operative mortality and an increased risk of recurrence of IE.
However, in patients who underwent emergency surgery we
observed improvements in clinical outcomes were achieved
without an increase in operative mortality or recurrence
of infectious endocarditis (4,5,71-73). These results were
comparable to those by Kang et al. (26). The mortality rate is
related to the extension of infectious lesion and the etiology
and the localization vegetation on the mitral valve leaflet
(4,59). Particular attention should be given to the risk of
embolization which has been reported to be particularly high
in the first week before diagnosis (7) and affecting the central
nervous system in up to 65% (1,2,74).
Nonetheless, several propensity matched analyses
showed contradictive results in terms of surgery morbidity
and mortality (26,75,76). This might be related to the
weight of embolic stroke and heart failure as determinants
of long-term mortality. However, treatment allocation bias,
underpowering and survivor bias affecting retrospective
studies surely have played a role (26,75,77).
In the sole RCT (26) the rate of embolism in patients
who received early surgery was markedly reduced as
compared to those who had conventional treatment. The
rate of embolism in the medical treatment arm was similar
to that reported in other prospective multicenter study (10)
or RCT (68).
We have reported that with a careful selection of patients
could result in low in-hospital mortality and 6-months
mortality (4,5,71,72). Poor prognostic factors, such as
moderate to severe congestive heart failure, altered mental
status and staphylococcal infection lead to increased
mortality, substantially comparable to that of other studies
(26,78-83). In our experience, patients with vegetations
>15 mm at high risk of mobility and located on the mitral
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valve, derive a considerable benefit from emergency surgical
treatment, as confirmed elsewhere (4,5,37,38,71,72).
Emergency surgical treatment within 48 hours can be
offered to patients who experienced an infection with severe
anatomic-pathological injuries with development of abscess,
extracardiac fistula or aortic root involvement. In this case
the risk of mortality is higher considering the technical
demand and the preoperative patient’s conditions.
In these patients an extensive and radical surgery is
necessary and homografts, conventional mechanical valves
or xenografts are used in similar complex endocarditis. In a
study reported by Harvard group (79) the abscess formation
had an incidence of 43.09% (n=131), which is higher
than the mean frequency (25–30%) reported by other
international studies, indicating the severity of the disease
treated in this cohort. In any case out of 131 patients with
abscess formation 40.5% received a mechanical valve and
while 29.5% were treated using xenograft. Selection of the
type of graft to be used should be driven by the resistance
to infection, as re-do surgery in case of reinfection is
particularly challenging and burdened by augmented risk. In
particular, reinfection of synthetic prostheses or prosthetic
materials is even more daunting and technically demanding
than in case of re-endocarditis on a previous homograft. In
this context, evidences on safety and durability of homograft
surgery has been widely reported. Already in 2001, Moon
et al. (84) revealed a reinfection rate of 2% at 10 years with
the majority of infection relapse following aortic valve
endocarditis surgery and occurring within the first year.
More recently Flameng et al. (85) showed a low recurrence
of endocarditis in patients who received a homograft to
treat complex IE. Excellent results are reported in the large
series of Arabkhani et al. (86) with a rate of intraoperative
mortality of 5.5% and durability up to 27 years.
Although some reports, as the current from Harvard (79),
praised the long-term outcomes of mechanical valves,
it cannot be neglected that these prostheses are bond
to a life-long anticoagulation which carries significant
risks. Additionally, the population normally afflicted by
endocarditis is relatively young and willing to conduct
an active life and oral anticoagulation means a significant
impairment in patient’s quality of life. Also, in case of female
patients, possibility of pregnancy is excluded. Moreover, if
we take into consideration the final objective of endocarditis
treatment, there is a significant lower infection recurrence
using homografts (87,88) even in the context of previous
prosthetic valve (89).
We reported the use of cryopreserved homograft for
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AVR in 210 patients (72) and one half of the patients had
endocarditis, 21% of these had an abscess formation. In
our series the use of a cryopreserved aortic homograft was
associated with no early reinfection and only 4 late relapses
of endocarditis. In presence of extensive infection, in young
patients with complex aorto-mitral endocarditis or aortic
root involvement we used a living pulmonary autograft
(90-95) or a double homograft valve replacement (4,5,71).
In our experimental studies from a mechanical point of
view, the use of a PA has shown efficacy compared to the
use of dacron (96,97).
We believe that in case of extensive infection performing
a quicker operation using a prosthetic valve with or without
a dacron graft provides a very unstable situation with
high potential for infection recurrence (72). Decision on
surgery is always deriving from a balance between the risk
of the procedure and the benefit achievable. Therefore,
considering the significant risk during endocarditis surgery
and the even higher risk represented by a redo-operation
for re-infection, we believe that the option to undergo a
minimal operation with known potential for re-infection
should be discouraged (Figure 3).
Conclusions
The indication for early surgery in IE has not yet been
appropriately defined and it differs significantly between the
European (5) and US guidelines (13) fueling the confusion
regarding the relative priority of surgical or medical
management. The ESC guidelines (5) individuates three
moments for the surgical indication. Emergency surgery
which is performed within 24 hours, urgent surgery which is
recommended within a few days and elective surgery which
is performed after 1–2 weeks of antibiotic therapy. Urgent
surgery is recommended for most cases of IE. Instead, the
AHA’s guidelines (13) define early surgery as “during the
initial hospitalization and before completion of a full course
of antibiotics.” We believe that in the presence of a clear
diagnosis of IE and when an indication for surgery has been
established, there are no proven benefits in delaying surgery
(4,26). The choice to perform an intervention for IE in
the early hours or with a delay of 48 hours depends on the
way the heart team works in the shared decision-making
process (4). There is evidence that has shown very low
mortality in centers of excellence with high level experience
in the management of complex patients and a RCT (26)
has supported the role of early surgery. However, further
evidences are needed to inform guidelines on the surgical
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Figure 3 Decision Tree for Distinguishing Early Surgery in HVE. LV, left ventricle; LA, left atrium; ACC/AHA, American College of
Cardiology/American Heart association; ESC, European Society of Cardiologists; HVE, heart valve endocarditis; LVEF, left ventricular
ejection fraction; TIA, transient Ischemic attack.

management of IE (Figure 3).
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